[EN] NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY [FR] NOUVEAUX DÉRIVÉS DE CYCLOHEXYL ET QUINUCLIDINYL CARBAMATE AYANT UNE ACTIVITÉ D'AGONISTE ADRÉNERGIQUE BETA2 ET UNE ACTIVITÉ D'ANTAGONISTE MUSCARINIQUE M3
NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY
申请人:ALMIRALL, S.A.
公开号:US20150329535A1
公开(公告)日:2015-11-19
The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
The first highly stereoselective approach to the mitotic kinesin Eg5 inhibitor HR22C16 and its analogues
作者:Sen Xiao、Xiao-Xin Shi
DOI:10.1016/j.tetasy.2009.12.029
日期:2010.2
A general method for the synthesis of the mitotic kinesin Eg5 inhibitor HR22C16 1 and its analogues based on protecting group (PG)-modulated highly diastereoselective Pictet-Spengler reaction of L-tryptophan methyl ester hydrochloride with meta-(RO)-benzaldehyde is described. By using the enantiomerically pure (1R,3S)-1,3-disubstituted tetrahydro-beta-carboline trans-4c as a common chiral synthon, HR22C16 1 and its analogues 2 and 3 were synthesized in 90.1%, 90.2%, and 86.5% overall yields, respectively. (C) 2010 Elsevier Ltd. All rights reserved.
CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES .
申请人:Almirall, S.A.
公开号:EP2934594B1
公开(公告)日:2019-09-04
US9518050B2
申请人:——
公开号:US9518050B2
公开(公告)日:2016-12-13
[EN] NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY<br/>[FR] NOUVEAUX DÉRIVÉS DE CYCLOHEXYL ET QUINUCLIDINYL CARBAMATE AYANT UNE ACTIVITÉ D'AGONISTE ADRÉNERGIQUE BETA2 ET UNE ACTIVITÉ D'ANTAGONISTE MUSCARINIQUE M3